Online citations, reference lists, and bibliographies.
← Back to Search

Integration Of Multimodality Approaches In The Management Of Malignant Pleural Mesothelioma.

Derlis Martino, H. Pass
Published 2004 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
More than half a century after the first descriptions of mesothelioma as a pathologic entity, satisfactory treatment is still elusive. Although relatively uncommon, the incidence of mesothelioma will most likely increase over the next 10-20 years. Advances have been made in understanding the pathogenesis, diagnosis, and staging, but they have not translated into markedly improved survival. Some use palliative treatment as the primary means of therapy even now. On the other hand, a cadre of individuals have studied how surgery, chemotherapy, and radiation therapy affect the disease. Although each individual modality has had limited success by itself, a multimodality approach has been documented to improve survival and quality of life. In addition, intriguing discoveries in immunology and gene profiling and therapy promise hope for further improvement. In this article, we will illustrate the current views on integrating these different approaches and delineate areas of active research.
This paper references
10.1097/00000421-199402000-00018
Recombinant Interferon Alpha‐2b in the Treatment of Diffuse Malignant Pleural Mesothelioma
A. Ardizzoni (1994)
10.1038/bjc.1992.200
High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study.
O. Solheim (1992)
Gene therapy for malignant mesothelioma: a novel approach for an incurable cancer with increased incidence in Louisiana.
P. Schwarzenberger (1998)
10.1089/HUM.1998.9.7-1083
Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma.
D. Sterman (1998)
Biological and immunological aspects of malignant mesothelioma.
M. Garlepp (1995)
10.1002/(SICI)1096-9896(199604)178:4<369::AID-PATH460>3.0.CO;2-8
MOLECULAR PATHOBIOLOGY AND IMMUNOLOGY OF MALIGNANT MESOTHELIOMA
H. Bielefeldt-Ohmann (1996)
10.1002/(SICI)1097-0215(19970502)71:3<476::AID-IJC28>3.0.CO;2-C
Transfection of the gene for B7‐1 but not B7‐2 can induce immunity to murine malignant mesothelioma
C. Leong (1997)
10.1016/S0003-4975(99)01038-3
Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.
V. Rusch (1999)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/0277-5379(89)90266-6
Radiation sensitivity of human lung cancer cell lines.
J. Carmichael (1989)
10.1002/1097-0142(19820601)49:11<2431::AID-CNCR2820491134>3.0.CO;2-W
Malignant mesothelioma of the pleura: Review of 123 patients
J. Brenner (1982)
10.1053/SONC.2002.30237
The epidemiology of mesothelioma.
M. Britton (2002)
10.1097/00001813-200301000-00008
Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma
S. van Ruth (2003)
10.1016/S0022-5223(96)70342-2
The importance of surgical staging in the treatment of malignant pleural mesothelioma.
V. Rusch (1996)
10.1016/0003-4975(95)00045-M
Characteristics of nine newly derived mesothelioma cell lines.
H. Pass (1995)
10.1016/S0003-4975(02)04474-0
A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma.
J. Friedberg (2003)
10.1007/BF02306613
Surgically debulked malignant pleural mesothelioma: Results and prognostic factors
H. Pass (2006)
10.1016/S0360-3016(02)04151-2
Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma.
A. Ahamad (2003)
10.1016/S0003-4975(10)62906-2
Surgical management of malignant mesothelioma.
G. A. Delaria (1978)
10.1002/1097-0142(20011015)92:8<2197::AID-CNCR1563>3.0.CO;2-F
Hyperthermic pleural perfusion with cisplatin
A. Yellin (2001)
Inhibition of hamster mesothelioma tumorigenesis by an antisense expression plasmid to the insulin-like growth factor-1 receptor.
H. Pass (1996)
10.5555/URI:PII:0093775481900427
Mesothelioma--the role for radiation therapy.
L. Brady (1981)
10.1002/(SICI)1097-0142(19990415)85:8<1740::AID-CNCR14>3.0.CO;2-9
Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura
S. Kasseyet (1999)
10.1016/S0360-3016(03)00287-6
Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma.
S. Yajnik (2003)
10.3109/08977199409015049
Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma.
D. R. Fitzpatrick (1994)
10.1067/MTC.2002.125817
Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma.
T. T. Lee (2002)
10.1053/SONC.2002.30231
Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine.
P. Baas (2002)
Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma.
C. Linder (1998)
Lymphocyte responses to phytohaemagglutinin in patients with asbestosis and pleural mesothelioma.
P. Haslam (1978)
10.1200/JCO.1994.12.6.1156
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
V. Rusch (1994)
10.1200/JCO.1989.7.8.1157
Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.
P. Ruffié (1989)
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
F. Ciardiello (2000)
10.1038/bjc.1990.207
Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody.
H. Dazzi (1990)
10.1158/1078-0432.CCR-0607-3
Gene Expression Profiles Predict Survival and Progression of Pleural Mesothelioma
H. Pass (2004)
10.1200/JCO.1999.17.1.25
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme.
T. Dorai (1994)
10.1053/SONC.2002.30234
New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents.
A. Nowak (2002)
Malignant mesothelioma of the pleura: clinical aspects and symptomatic treatment.
M. Law (1984)
10.1002/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO;2-N
Intrapleural treatment with recombinant gamma‐interferon in early stage malignant pleural mesothelioma
C. Boutin (1994)
10.1016/S0169-5002(03)91858-7
O-200 Neoadjuvant chemotherapy followed by pleuropneumonectomy for pleural mesothelioma: a multicenter phase II trial of the SAKK
R. Stahel (2003)
10.1089/JIR.1990.10.531
Phase II Evaluation of Recombinant Interferon-β (LFN-βser) in Patients with Diffuse Mesothelioma: A Southwest Oncology Group Study
D. V. Hoff (1990)
10.1007/BF00918702
High frequency of immune dysfunctions in asbestos workers and in patients with malignant mesothelioma
F. Lew (2004)
[Gene expression profiling in human mesothelioma cells using DNA microarray and high-density filter array technologies].
S. Mohr (2001)
10.1016/S1010-7940(02)00735-2
The management of malignant pleural mesothelioma.
G. Maggi (2003)
10.1016/S0039-6109(16)44532-9
Surgical treatment of asbestos-related disease of the chest.
L. Faber (1988)
10.1016/S0003-4975(10)64593-6
Extrapleural pneumonectomy for diffuse, malignant mesothelioma.
M. Davalle (1986)
10.1007/BF01600160
The influence of the diagnostic technique on the histopathological diagnosis in malignant mesothelioma
T. Gelder (2005)
10.1111/j.1365-2249.1991.tb05593.x
Asbestos fibres inhibit the in vitro activity of ymphokine‐activated killer (LAK) cells from healthy individualsand patients with malignant mesothelioma
L. S. Manning (1991)
10.1002/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO;2-3
Intrapleural administration of interleukin‐2 for the treatment of patients with malignant pleural mesothelioma
P. Astoul (1998)
Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor.
A. Marrogi (2000)
10.1093/JNCI/95.8.598
Using gene expression ratios to predict outcome among patients with mesothelioma.
G. Gordon (2003)
10.1378/CHEST.120.4.1167
Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results.
H. Schouwink (2001)
Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study.
G. Brewer (2000)
10.1016/S0169-5002(00)00217-8
Localised spontaneous regression in mesothelioma -- possible immunological mechanism.
B. Robinson (2001)
10.1067/MTC.2002.128577
Pleural mesothelioma in 2002: going somewhere very slowly.
H. Pass (2002)
10.1016/S1010-7940(02)00273-7
The management of malignant pleural mesothelioma; single centre experience in 10 years.
T. Aziz (2002)
10.1016/S0169-5002(00)00152-5
Surgical approach to pleural diffuse mesothelioma in Japan.
K. Takagi (2001)
Malignant pleural mesothelioma. Extrapleural pneumonectomy and pleurectomy.
K. Allen (1994)
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
10.1016/S1010-7940(01)00995-2
Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control.
A. Martin-Ucar (2001)
10.1016/S0022-5223(19)36577-8
The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.
V. Rusch (1991)
10.1378/CHEST.116.SUPPL_3.455S
Emerging translational therapies for mesothelioma.
H. Pass (1999)
10.1016/S0360-3016(02)04150-0
Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation.
K. Forster (2003)
10.1016/S0022-5223(98)70274-0
Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.
H. Pass (1998)
10.1038/sj.bjc.6690650
VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
Y. Ohta (1999)
10.1007/BF02303746
Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma
H. Pass (2006)
10.1165/AJRCMB.22.5.3930
Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities.
C. Robinson (2000)
10.1159/000227208
A new device for the treatment of pleural malignancies: intrapleural chemohyperthermia preliminary report.
P. Y. Carry (1993)
Effect of interferon-alpha 2a on malignant mesothelioma.
T. Christmas (1993)
10.1038/bjc.1994.410
Autocrine stimulation of a human lung mesothelioma cell line is mediated through the transforming growth factor alpha/epidermal growth factor receptor mitogenic pathway.
I. Mórocz (1994)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1002/1097-0142(19821001)50:7<1245::AID-CNCR2820500704>3.0.CO;2-H
High‐dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma
N. Dimitrov (1982)
10.1378/CHEST.116.SUPPL_3.450S
Pleuropneumonectomy in the treatment of malignant pleural mesothelioma.
S. Grondin (1999)
10.1016/S0022-5223(99)70297-7
Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study.
G. B. Ratto (1999)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1053/SONC.2002.30236
Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience.
P. Sugarbaker (2002)
10.1038/sj.bjc.6600118
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
J. van Haarst (2002)
10.1007/S11864-000-0047-4
Malignant pleural mesothelioma
H. Kindler (2000)
10.1016/S0959-8049(02)00668-8
The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992).
P. Baas (2003)
10.1002/JSO.2930450109
Malignant pleural mesothelioma: A survival study
J. Harvey (1990)
10.1136/thorax.55.9.731
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
J. Edwards (2000)
10.1016/S0039-6109(02)00033-6
Malignant mesothelioma: options for management.
S. Singhal (2002)
10.7326/0003-4819-96-6-746
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients.
A. Chahinian (1982)
10.1097/00000372-199106000-00014
Malignant mesothelioma presenting as Sister Joseph's nodule.
K. Chen (1991)
10.1016/0011-3840(93)90029-G
Malignant pleural mesothelioma.
H. Pass (2004)
10.1002/SSU.2980060510
Diagnosis and treatment of pleural mesothelioma.
V. Rusch (1990)
[Malignant pleural mesothelioma: diagnosis, therapy and prognosis].
S. Geroulanos (1990)
Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma.
J. Edwards (2002)
10.1562/0031-8655(2001)073<0410:PTFMMP>2.0.CO;2
Photodynamic Therapy for Malignant Mesothelioma: Preclinical Studies for Optimization of Treatment Protocols¶
H. Schouwink (2001)
10.1056/NEJMOA021967
A gene-expression signature as a predictor of survival in breast cancer.
M. J. van de Vijver (2002)
10.1002/SSU.2980110507
Intracavitary photodynamic therapy for malignant pleural mesothelioma.
H. Takita (1995)
10.1002/1097-0215(200002)9999:9999<::AID-IJC1094>3.0.CO;2-M
Gene expression profiling of malignant mesothelioma cell lines: cDNA array study
E. Kettunen (2001)



This paper is referenced by
10.1016/j.ijrobp.2009.06.037
Radiotherapy in malignant pleural mesothelioma.
M. McAleer (2009)
10.1510/icvts.2007.166546
The role of muscle flap in preventing bronchus stump insufficiency after pneumonectomy for malignant pleural mesothelioma in high-risk patients.
M. Beshay (2008)
10.1016/J.BBADIS.2006.04.001
Autoantibody biomarkers in the detection of cancer.
Y. S. Cho-Chung (2006)
10.1016/S0761-8417(05)84834-5
Traitement médical du mésothéliome pleural malin. Place du Pemetrexed dans la stratégie actuelle
J. Margery (2005)
10.3807/JOSK.2015.19.1.069
In vivo Optical Coherence Tomography Imaging of the Mesothelium Using Developed Window Models
Y. Ahn (2015)
10.1158/1055-9965.EPI-07-0607
Profiling Tumor-Associated Markers for Early Detection of Malignant Mesothelioma: An Epidemiologic Study
M. Amati (2008)
10.1158/1535-7163.MCT-04-0243
Human mesothelioma cells exhibit tumor cell–specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase
Maria E. Ramos-Nino (2005)
10.1016/J.REMN.2010.08.008
Utilidad de la PET-TAC 18F-FDG en la valoración prequirúrgica del mesotelioma pleural maligno tras quimioterapia neoadyuvante
Javier Orcajo Rincón (2011)
10.1517/14712598.6.4.391
Ranpirnase – an antitumour ribonuclease: its potential role in malignant mesothelioma
N. Pavlakis (2006)
10.1186/1748-717X-4-35
Comparison of CT and integrated PET-CT based radiation therapy planning in patients with malignant pleural mesothelioma
B. Pehlivan (2009)
10.1158/1078-0432.CCR-08-0360
Osteopontin Levels in an Asbestos-Exposed Population
E. Park (2009)
10.1097/RLI.0b013e3181817b3d
Computed Tomography, Positron Emission Tomography, Positron Emission Tomography/Computed Tomography, and Magnetic Resonance Imaging for Staging of Limited Pleural Mesothelioma: Initial Results
C. Plathow (2008)
10.1136/oem.2009.049205
Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein
A. Cristaudo (2009)
10.1016/j.taap.2013.10.025
Combination of ascorbate/epigallocatechin-3-gallate/gemcitabine synergistically induces cell cycle deregulation and apoptosis in mesothelioma cells.
S. Martinotti (2014)
10.1056/nejmoa051185
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
H. Pass (2005)
10.1016/J.EJCTS.2006.11.046
A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.
M. Lucchi (2007)
10.1515/cclm-2012-0314
A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels
E. Park (2012)
10.1200/JCO.2008.19.8523
Malignant pleural mesothelioma.
A. Tsao (2009)
10.1177/172460081002500307
Comparison between Plasma and Serum Osteopontin Levels: Usefulness in Diagnosis of Epithelial Malignant Pleural Mesothelioma
A. Cristaudo (2010)
10.1016/j.jprot.2011.09.026
Proteomic study of malignant pleural mesothelioma by laser microdissection and two-dimensional difference gel electrophoresis identified cathepsin D as a novel candidate for a differential diagnosis biomarker.
Mutsumi Hosako (2012)
10.14288/1.0071526
Molecular imaging of mesothelin expressing cancers
Ripen Misri (2010)
10.1097/00005382-200605000-00006
Preoperative Evaluation of Patients With Malignant Pleural Mesothelioma: Role of Integrated CT-PET Imaging
M. Truong (2006)
10.3816/CLC.2009.n.005
Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma.
A. Tsao (2009)
10.1259/bjr.20170814
18F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center.
H. S. Elliott (2018)
10.1016/j.lungcan.2011.08.002
Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study.
K. Kuribayashi (2012)
10.1510/icvts.2009.223255
Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything?
M. Lucchi (2010)
10.1093/icvts/ivz303
18F-fluorodeoxyglucose positron emission tomography in malignant pleural mesothelioma: diagnostic and prognostic performance and its correlation to pathological results.
F. Lococo (2020)
10.1007/s00204-010-0580-2
Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos
M. Gube (2010)
10.1007/174_2017_50
Diseases of the Pleura and the Chest Wall
Claus Peter Heussel (2009)
10.1016/J.REMNGL.2010.08.003
[Usefulness of 18F-FDG PET-CT in the presurgical assessment of malignant pleural mesothelioma treated with neoadjuvant chemotherapy].
Javier Orcajo Rincón (2011)
10.2486/INDHEALTH.46.535
Asbestos-related occupational lung diseases in NSW, Australia and potential exposure of the general population.
E. Park (2008)
10.13104/JKSMRM.2013.17.3.232
Added Value of Magnetic Resonance Imaging in Staging of Malignant Pleural Mesothelioma
Eunsol Lee (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar